Study Progression on Non-small Cell Lung Cancer with EGFR Mutation 
Treated by Immune Checkpoint Inhibitors

In recent years, epidermal growth factor receptor tyrosine kinase inhibitors have been recommended by many guidelines as first-line drugs for advanced non-small cell lung cancer (NSCLC) with EGFR gene mutations and no resistance. However, with the prolongation of medication time, most appear acquire...

Full beskrivning

Sparad:
Bibliografiska uppgifter
Huvudupphovsmän: Rilan BAI, Naifei CHEN, Jiuwei CUI
Materialtyp: Artigo
Språk:Chinês
Publicerad: Chinese Anti-Cancer Association; Chinese Antituberculosis Association 2018-08-01
Serie:Chinese Journal of Lung Cancer
Ämnen:
Immune checkpoint inhibitors
Lung neoplasms
EGFR mutation
PD-L1
Länkar:http://dx.doi.org/10.3779/j.issn.1009-3419.2018.08.11
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk